HENDERSON, Nev. ( TheStreet) -- Spectrum Pharmaceuticals (SPPI - Get Report) and TopoTarget are collaborating on the development of the lymphoma drug belinostat, but the partners aren't on the same page over the outcome a pivotal study -- yet.
On Friday morning, TopoTarget, a Danish drug firm, announced that the primary endpoint had been meet for the belinostat phase II trial for patients with peripheral T-cell lymphoma (PTCL).
Spectrum, however, chose not to participate in TopoTarget's announcement. Instead, Spectrum filed an 8-K Friday evening, characterizing the belinostat study results as "preliminary" and said a definitive verdict wouldn't be determined until final data are collected and analyzed at the end of the fourth quarter.
"Our conservatism makes us more cautious than TopoTarget," said Shiv Kapoor, Spectrum's vice president for strategic planning and investor relations, in an email. "Although we are more optimistic about the final results of the trial, we want to wait until final results to confirm whether we met the
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts